Huma-Pronol (Propranolol Hydrochloride)

Huma‑Pronol is indicated for several therapeutic purposes where beta‑blockade provides clinical benefit, particularly in cardiovascular and neurologic disorders.

• Hypertension (high blood pressure)
• Angina pectoris (chest pain due to coronary artery disease)
• Prevention of myocardial infarction and secondary cardiovascular events
• Management of certain cardiac arrhythmias, such as supraventricular tachycardia
• Prophylaxis of migraine headaches
• Control of essential tremor, especially when other agents are insufficient

• Propranolol hydrochloride acts as a non‑selective antagonist of β‑1 and β‑2 adrenergic receptors. By blocking β‑1 receptors in the heart, it reduces heart rate, myocardial contractility, and the release of renin from the kidneys. Inhibition of β‑2 receptors leads to decreased peripheral vasodilation and bronchial smooth‑muscle tone. The combined effect lowers cardiac output and blood pressure, stabilizes cardiac rhythm, and diminishes the frequency of migraine attacks.

Like other beta‑blockers, Huma‑Pronol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common

• Fatigue or generalized weakness
• Dizziness or light‑headedness, especially on standing
• Cold extremities or reduced peripheral circulation
• Gastrointestinal upset such as nausea or abdominal cramps

Serious

• Severe bradycardia or heart block
• Marked hypotension
• Bronchospasm in patients with asthma or chronic obstructive pulmonary disease
• Depression, mood changes, or worsening of psychiatric conditions

Before prescribing Huma‑Pronol, clinicians should evaluate patient history and monitor for conditions that could be worsened by beta‑blockade.

• Contraindicated in patients with severe bradycardia or second‑/third‑degree AV block
• Use with caution in uncontrolled heart failure
• Avoid in patients with active asthma or severe chronic obstructive pulmonary disease
• May exacerbate peripheral vascular disease
• Can mask hypoglycaemic symptoms in diabetic patients
• Pregnancy safety category is unknown; consider risk‑benefit ratio
• Monitor renal and hepatic function in patients with impairment

Propranolol can alter the pharmacokinetics or pharmacodynamics of several medicines; careful review of a patient’s medication list is recommended.

Avoid

• Concomitant use with other non‑selective beta‑blockers
• Calcium channel blockers that affect AV nodal conduction (e.g., verapamil, diltiazem)
• MAO inhibitors or abrupt discontinuation of clonidine

Use with caution

• Antidiabetic agents (risk of masking hypoglycaemia)
• Antidepressants, especially SSRIs and tricyclics
• NSAIDs or other antihypertensives (may blunt blood‑pressure reduction)